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Metastasisp300 is a transcription cofactor for a number of nuclear proteins. Most studies of p300 have focused on the reg-
ulation of its function, which primarily includes its role as a transcription co-factor for a number of nuclear pro-
teins. In this study,we found that p300washighly phosphorylated and its levelwas decreasedduringmitosis and
tumorigenesis. In vitro and in vivo experiments aimed showed that cyclin-dependent kinase 1 (CDK1) and ERK1/
2 phosphorylated p300 on Ser1038 and Ser2039. Mutations of Ser1038 and Ser2039 increased p300 protein sta-
bility and levels. Inhibition of p300 degradation by blocking its phosphorylation decreased the proliferation and
metastasis activity of lung cancer cells, indicating that p300 acts as a tumor suppressor in lung cancer tumorigen-
esis. Investigation of themolecularmechanism showed that blocking p300 phosphorylation disrupted chromatin
condensation and the increased the acetylation of histone H3. Analysis of cell cycle progression in HA-p300-S2A-
expressing cells byﬂow cytometry showed that the p300mutants arrested the cells at S-phase or delayed themi-
totic entry and exit. The expression of several important oncogenes,MMP-9, vimentin, β-catenin, N-cadherin and
c-myc, was negatively regulated by p300. In conclusion, during lung tumorigenesis, a phosphorylation-mediated
decrease in p300 level enhanced oncogene expression during interphase and decreased histone H3 acetylation
during mitosis, which promoted lung cancer progression.
© 2014 Published by Elsevier B.V.1. Introduction
Chromatin remodeling regulated by histone modiﬁcation is a very
important step for gene expression [1]. Acetylation is one of the major
post-translational modiﬁcations [2]. Among the proteins that regulate
histone acetylation, histone acetyltransferases (HAT; e.g., CREB binding
protein (CBP), p300, and GCN5) add acetyl groups [3], whereas histone
deacetylases (HDACs) remove acetyl groups [3,4]. Histone acetylation al-
ters the higher-order chromatin structure and plays a central role in the
regulation of gene expression, as well as in the pathogenesis of a broad
range of diseases, including cancer [5]. Tight control ofHAT andHDACac-
tivity is critical to ensure precise histone acetylation and gene activation
[6]. p300 is a transcriptional co-activator for multiple transcription
factors in many cell types, and p300 participates in a number of critical
cellular processes, including cell cycle regulation, differentiation, genes and Biosignal Transduction,
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g).
vier B.V.expression, and apoptosis [7–10]. However, how cells modulate p300
activity and protein expression is not entirely clear.
To understand these regulatory mechanisms, research has focused,
for the most part, on the identiﬁcation of sequence-speciﬁc DNA-
binding proteins, such as the Sp1 family of transcription factors, that in-
teract with the promoter and enhancer elements of genes regulated
during cellular activation [11]. More recently, however, it has become
apparent that non-DNA-binding transcriptional co-activators, such as
p300 and CREB-binding protein (CBP), previously thought to function
primarily as “scaffold” proteins between DNA-bound transcription
factors and the basal transcription complex, play a critical regulatory
role by integrating diverse signaling pathways to selectively induce
gene expression [10]. Although many previous studies have demon-
strated that p300 plays an important role in cell cycle progression
[12,13], the regulation of p300 during mitosis is not fully understood.
In addition, many studies have focused on the role of p300 during
tumorigenesis [14–17]. Several studies have shown that p300 is over-
expressed in solid tumor malignancies, whichmight affect tumorigene-
sis and cancer progression [18,19]. For example, p300 is overexpressed
and associated with poor prognosis in hepatocellular carcinoma [19]. In
addition, p300 is overexpressed in prostate and colorectal carcinomas
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oncoproteins and is often mutated truncated in breast, colorectal, and
pancreatic cancers, indicating that p300may repress cancer progression
by acting as a tumor suppressor [9,15,23,24]. In fact, previous studies
have shown that p300 activates p53 to repress the proliferation of
cancer cells [25–27]. Thus, the role of p300 in tumor progression
appears to be complicated and requires further study.
Most proteins involved in the control of cell growth are regulated by
phosphorylation. For example, mitosis in vertebrates is triggered by
cyclin-dependent kinase 1 (CDK1). During G2 phase, cyclin B1 is accu-
mulated in the cytoplasm, and forms a complex with CDK1. Subse-
quently, CDK1 is inactivated by phosphorylation at Thr14 and Thr15
[28]. During late G2 phase, dephosphorylation by phosphatase CDC25
activates CDK1, and most of the cyclin B1/CDK1 complexes rapidly
translocate from the cytoplasm to the nucleus as the nuclear envelope
breaks down [28]. p300 is phosphorylated at several sites by various
kinases, including extracellular signal-activated kinases (e.g., protein
kinase [PK] A, PKC, and Akt and mitogen-activated protein kinases
[MAPK]). Phosphorylation regulates p300 activity and expression
under different physiological conditions [29–31]. For example, ERK1/
2-mediated p300 phosphorylation on Ser2279, Ser2315, and Ser2366
stimulates HAT activity [32]. Previous studies have also shown that
the PKC- and salt-inducible kinase 2-mediated p300 phosphorylation
on Ser89 inhibits the HAT activity of p300 [29,33], whereas phosphory-
lation on Ser1834 by Akt increases its HAT activity [34]. In addition, a re-
cent study revealed that p38MAPK phosphorylated p300 on Ser1834 to
induce p300 degradation as part of the DNA damage response [35,36].
Furthermore, studies have shown that phosphorylation by ataxia-
telangiectasia mutated (ATM) on Ser106 of p300 is important for p300
stabilization in response to double-strand breaks (DSBs) induced by
ionizing radiation (IR) and etoposide [37,38]. Thus, different residues
of p300 are phosphorylated by different kinases under various condi-
tions. In this study, we demonstrated that p300 levels were tightly reg-
ulated by phosphorylation and that p300 phosphorylation modulated
lung cancer progression by affecting cell cycle progression and onco-
genes expression.
2. Material and methods
2.1. Reagents
Monoclonal antibodies against, cyclin B1, glutathione S-transferase
(GST), and CDK1 and polyclonal antibodies against p-histone H3 (S10)
were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Monoclonal antibody against p300 and matrigel were obtained from
BD Biosciences PharMingen (San Diego, CA). Polyclonal antibodies
against p-p300 (pS1038) and p-p300 (pS2039) were made by Kelowna
International Scientiﬁc Inc. (Taipei, Taiwan). Polyclonal antibodies
against Sp1 and acetyl-H3 were purchased from Upstate Biotechnology
(Waltham, MA). Polyclonal antibodies against histone H3 were pur-
chased from Millipore (Billerica, MA). Polyclonal antibodies against
vimentin, N-cadherin and c-myc were purchased from Epitomics
(Burlingame, CA). CDK1/Cyclin B1 kinase and polyclonal antibodies
against β-catenin were purchased from Cell Signaling Technology
(Danvers, MA). [γ-32P]ATP (6000 Ci/mmol) was purchased from
PerkinElmer Life Sciences (Waltham, MA). All other chemical reagents
used were of the highest purity obtainable.
2.2. Cell culture
Human cervical adenocarcinoma HeLa cells, lung adenocarcinoma
A549 cells, H1299 cells, and CL (CL1-0 and CL1-5) cell lines provided
by Dr Pan-Chyr Yang [39], were grown in 90% DMEM containing 10%
fetal bovine serum, 4 mM L-glutamine, 100 μg/ml streptomycin sulfate,
1 mM sodium pyruvate, and 100 units/ml penicillin G sodium at 37 °C
and 5% CO2 in an incubator.2.3. Puriﬁcation of GST fusion proteins
To purify GST-p300, Escherichia coli BL21 (DE3) cells were cultured
to mid-log phase in 200 ml of LB medium containing ampicillin
(50 mg/ml). The detailed protocol is the same as that previously
reported [32].
2.4. In vitro CDK1 kinase assay
For the in vitro phosphorylation analysis, the different GST-p300
fragments and p300 mutants with point mutations were
puriﬁed from E. coli BL21 (DE3). Different dosages of active CDK1
were used to examine p300 phosphorylation in vitro. Each reaction
(20 μl) contained 1 mg of puriﬁed p300, 15 ng of CDK1-cyclin B, 2 μl of
[γ-32P]ATP (6000 Ci/mmol), 1 mM ATP, and 3 μl of 5× kinase buffer
containing 500 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM EDTA, and 1
mM DTT. The phosphorylation reactions were incubated at 30 °C
for 15 min. After the incubation, one-half of the reaction was added to
10 μl of 2× electrophoresis sampling buffer, which was then heated to
95 °C for 5 min. Proteins in the mixtures were immediately separated
using SDS-PAGE, followed by drying and autoradiography.
2.5. Generation of bitransgenic mice (Scgb1a1-rtTA/TetO-Kras4bG12D)
Two transgenic lines were acquired from Jackson Lab (Bar Harbor,
MA, USA) and maintained at the National Laboratory Animal Center in
Taiwan. The Scgb1a1-rtTA transgenic mice expressed the reverse tetra-
cycline trans-activator (rtTA) protein under the control of Scgb1a1
(secretoglobin, family 1A, member 1) promoter. The TetO-Kras4bG12D
transgenic mice expressed activated Kras (Kras4bG12D) under the regu-
lation of a tetracycline-responsive promoter element (TRE; tetO). After
mating, PCR genotyping was performed for detection of Scgb1a1-rtTA
and TetO-Kras4bG12D in bitransgenic mice. Activated Kras expression
in the bitransgenic mice was induced by administration of doxycycline
(0.5 g/l) to the drinking water, starting at the age of 2 months.
2.6. Western blot analysis
Whole-cell extracts were fractionated using sodiumdodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a
nitrocellulose membrane using a transfer apparatus in accordance
with the manufacturer's protocols (Bio-Rad). After the membrane had
been incubated with 3% nonfat milk in Tris-buffered saline Tween 20
(TBST) [10 mM Tris (pH 8.0), 150 mM NaCl, and 0.5% Tween 20] for
60 min, it was washed once with TBST and incubated with antibodies
against cyclin B1 (1:5000), CDK1 (1:3000), p300 (1:2000), p-p300
(S1038) (1:1000), p-p300 (S2039) (1:1000), HA (1:2000), actin
(1:3000), tubulin (1:5000), acetyl-H3 (1:5000), p-H3 (S10) (1:5000),
histone H3 (1:1000), CBP (1:1000), MMP9 (1:1000), MMP7 (1:1000),
vimentin (1:5000), c-myc (1:3000), b-catenin (1:1000) or N-cadherin
(1:1000) at 4 °C for 12 h. The membranes were washed three times
for 10 min each and incubated with a 1:3000 dilution of horseradish-
peroxidase-conjugated anti-mouse anti-rabbit or anti-rat antibodies
for 120 min at room temperature (approximately 25 °C). The blots
were washed with TBST three times and developed using an electro-
chemiluminescence system (Amersham Biosciences Corp., Piscataway,
NJ) in accordancewith themanufacturer's protocols.Western blot anal-
yses were developed in the linear range used for densitometry.
2.7. Immunoﬂuorescence
HeLa cells were seeded onto glass slides overnight and ﬁxedwith 4%
paraformaldehyde in phosphate-buffered saline (PBS) at 4 °C for 15
min. The cells were then rinsed with PBS two times and permeabilized
with 1% Triton X-100 for 7 min. Next, the cells were pretreated with 1%
bovine serum albumin (BSA) in PBS at 25 °C for 60min, incubated with
Fig. 1. Regulation of p300 level in cell cycle progression. A. HeLa cells were treated with 45 ng/ml nocodazole for 16 h to synchronize at prometaphase (M), whereas cells without any
treatment (N). The lysates were harvested for detection of p300 level by immunoblotting with anti-p300 antibodies. Cyclin B1 was used as a mitotic marker and tubulin as a loading in-
ternal control. ThemRNA level of p300 andGAPDHwas studied by using RT-PCR (a). p300 level was studied in the normal and tumor tissues of a clinical lung cancer patient (b). p300 and
CBP levels were studied in the lung cancer cell lines, CL1-0 and CL1-5, and themRNA level of p300 and GAPDHwas also studied by using RT-PCR (c). B. All experiments in the panel (a) of
Fig. 1A were performed independently in triplicate, and the fold was normalized with normal (N) cells. Statistical analysis was performed using Student's t test (**P b 0.01). C. HeLa cells
were treated with nocodazole for indicated time points. Cells lysates were harvested for immunoblotting with antibodies against p300, cyclin B1, tubulin, acetyl-histone H3 (ac-H3) and
histoneH3 (H3) (a). Nocodazole-treatedmitotic HeLa cellswere re-cultured in freshmediumand then incubatedwith indicated time points, and thenwere harvested for immunoblotting
with antibodies against p300, cyclin B1, tubulin, acetyl-histone H3 (ac-H3) and histone H3 (H3) (b). D. p300 was studied by immunoﬂuorescence assay with anti-p300 and anti-Sp1 an-
tibodies in HeLa cells. The secondary antibodies for anti-p300 and anti-Sp1 were conjugated with FITC and Cy5, respectively. DNA was stained with DAPI and then cells were examined
with immunoﬂurescence microscope. p300 was studied in the different cellular phases shown here, interphase (I), prophase (P), metaphase (M), anaphase (A) and telophase (T).
E. HA-p300 or HA-control plasmid was transfected into HeLa cells for 24 h following with or without nocodazole treatment, and then lysates were harvested to study the over-
expressed p300 byWestern blotting with anti-HA, anti-cyclin B1 and anti-tubulin antibodies. F. HeLa cells were synchronized with double thymidine (2mM) blockage at G1/S boundary
and released in fresh culturemedium for 10 h (M). The lysates of normal andmitotic cells were collected for studying of p300 level byWestern blottingwith anti-p300, anti-cyclin B1 and
anti-tubulin antibodies. (G). Normal or nocodazole-treated mitotic HeLa cells were respectively treated with 100 μM cycloheximide (CHX) for indicated time points followed by immu-
noblottingwith antibodies against p300, cyclin B1 and tubulin. Normal or nocodazole-treatedmitotic HeLa cells were respectively treatedwith 100 μMcycloheximide (CHX) for indicated
time points followed by immunoblotting with antibodies against p300, cyclin B1 and tubulin (a). After three independent experiments, the level of p300 protein was quantiﬁed (b).
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monoclonal antibodies at a dilution of 1:200 for 1 h, and treated with
FITC-conjugated donkey anti-mouse immunoglobulin G (IgG) polyclon-
al antibodies and cyanine 5-conjugated donkey anti-rabbit IgG poly-
clonal antibodies (Jackson ImmunoResearch Laboratories, Inc.) at a
dilution of 1:250 for 1 h. Finally, the cells were washed with PBS,
mounted in 90% glycerol containing DAPI, and analyzed using animmunoﬂuorescence microscope (Personal DV Applied Precision,
Issaquah, WA) with deconvolution function (softWoRx).
2.8. In vitro calf intestinal alkaline phosphatase (CIP) assay
For in vitro dephosphorylation of p300, themitotic cell extractswere
combinedwith 10 units of alkaline phosphatase in CIP buffer containing
1139S.-A. Wang et al. / Biochimica et Biophysica Acta 1843 (2014) 1135–114950mM Tris, pH 7.9, 100mMNaCl, 10 mMMgCl2, and 1 mMdithiothre-
itol in CIP buffer, and the mixture was incubated at 37 °C for 1 h.
2.9. Immunoprecipitation
Cell extracts were prepared, and the protein concentration was de-
termined using a bicinchoninic acid (BCA) protein assay kit. An equal
amount of protein was used in each experiment. The supernatants
were transferred to new tubes and incubatedwith anti-p300 antibodies
at a dilution of 1:200 at 4 °C for 12 h. The immunoprecipitated pellets
were subsequently incubated with protein G-Sepharose, washed three
timeswith lysis buffer, and separated on SDS-PAGE. After electrophoresis,
the gels were processed for immunoblotting with anti-CDK1 (1:2000)
antibodies.
2.10. Fluorescence-activated cell sorting (FACS) analysis
The cells were washed with ice-cold PBS and ﬁxed in cold absolute
ethanol at 4 °C for 4 h. The cells were then washed twice with PBS.
After treating with 10 mg/ml RNase A at 37 °C for 30 min, cells were
stained with 50 mg/ml propidium iodide at room temperature for
30min. Finally, cells were analyzed using a ﬂow cytometer (FACSCalibur;
BD Biosciences, San Jose, CA, USA).
2.11. Clinical specimens from patients with lung adenocarcinoma
Clinical specimens were collected after clinical resection from
patients with lung adenocarcinoma who underwent surgery at the
Department of Surgery of the National Cheng Kung University Hospital.
Collection of human specimens conformed to the human ethics andwas
approved by the Clinical Research Ethics Committee at National Cheng-
Kung University Medical Center.
2.12. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA of cells was isolated with a TRIzol RNA extraction kit, and
3 mg of RNA was subjected to RT-PCR with SuperScript III. The primers
used to perform PCR for p300 were 5′-AAATACTGCTCCAAGCTC-3′
(sense) and 5′-TCCAATTAGGATTTCATG-3′ (antisense), and primers
used to perform PCR for glyceraldehyde-3-phosphate dehydrogenase
were 5′-CCATCACCATCTTCCAGGAG-3′ (sense) and 5′-CCTGCTTCACCA
CCTTCTTG-3′ (antisense). PCR products were separated by 1% agarose
gel electrophoresis and visualized by ethidium bromide staining.
2.13. Histological analysis and immunohistochemistry
Lungs excised from bitransgenic mice or clinically resected speci-
menswere ﬁxed in 10% formaldehyde for 24 h, dehydrated and embed-
ded in parafﬁn. Sections (5 μM)were cut and stained with hematoxylin
and eosin. For immunohistochemistry, sectionswere dewaxed in xylene
and rehydrated in a graded series of ethanol. Endogenous peroxidases
were blocked by 0.3% hydrogen peroxide in phosphate-buffered saline
(PBS) for 30 min. Histological sections, blocked with 3% bovine serumFig. 2. Phosphorylation of p300 at Ser1038/2039 by CDK1 duringmitosis.A. Normal (N) or noco
phosphatase, CIP (lanes 1–5); cells without CIP added were as a negative control (lanes 6 and 7)
lysate of normal andmitotic HeLa cells was prepared for an immunoprecipitation (IP) assay usin
CDK1 and p300. Cyclin B1 was used as a mitotic marker and tubulin as a loading control. C. Do
nuclear hormone receptor-binding domain (NR), three cysteine-histidine-rich regions (CH-1, -2
(HAT) and glutamine-rich domain (Q-rich) shown in the diagram. D. The GST-p300 fragments
nucleolin (amino acids 599–710) were combined with [γ-32P]ATP and activated CDK1 for an in
SDS-PAGE and then autoradiography (lanes 1–7) and Coomassie blue staining to conﬁrm the p
599–710) was as a positive control (lane 7) [42]. E. The GST-p300 fragment (amino acids 952–
E. coli and puriﬁed to perform in vitro kinase assay in the presence of [γ-32P]ATP and activated
proteins assayed by Coomassie blue staining were the internal control (lanes 5–8). F. Peptide a
with anti-peptide without phosphorylation and anti-phospho-p300 (S1038) and anti-phospho
phorylation at Ser1037 or Ser1038 were synthesized to do dot blotting with anti-phospho-p300
assay with antibodies against p300, phospho-p300 (S1038), phospho-p300 (S2039), CDK1, cycalbumin in PBS, were incubated with appropriate diluted primary anti-
body for 2 h at room temperature. The immunoreactivitywas visualized
with a Vectastain ABC kit (Vector Laboratories, Burlingame, CA) and
photographed under Olympus BX-51 microscope (Olympus, Melville,
NY).
2.14. Wound-healing and Transwell migration assay
After overexpression of p300 in CL1-5 cells for 24 h, the linear
wound of cellular monolayer was created by scratching conﬂuent cell
monolayer using a plastic pipette tip. The monolayer of scratched cell
was washed with PBS to remove the debris. After incubation at 37 °C
for 24 h, area of migration was photographed under light microscope
for evaluation. The cell migration assay was performed using Transwell
system with an 8-μM pore size polycarbonate ﬁlter membrane. After
overexpression of p300 in CL1-5 cells for 24 h, cells were trypsinized
and suspended in serum-free DMEM. Upper wells were ﬁlled with cell
suspensions (2 × 104) in serum-free DMEM and lower wells were ﬁlled
with DMEM containing 10% fetal bovine serum. After incubation for 6 h
at 37 °C, the lower side of ﬁlter membrane was ﬁxed with 10% formal-
dehyde and stained with DAPI for 3 min. The migrated cells were
counted under a ﬂuorescent microscope.
2.15. In vitro Matrigel-combined invasion assay
Cellular invasive property of cells was analyzed by invasion assay
using the 24-well plate Transwell system with an 8-μM pore size poly-
carbonate ﬁlter membrane. The ﬁlter membrane was coated with
15 μg (45 μg/cm2) of Matrigel. The cell suspensions were seeded to
the upper compartment of the Transwell chamber at the cell density
of 2 × 104 in 100 μl of medium. After 24 h, the ﬁlter membrane was
ﬁxed with methanol for 10 min. The opposite surface of the ﬁlter mem-
brane facing the lower chamber was stained with DAPI for 3 min and
the migrated cells were then counted under a ﬂuorescent microscope.
2.16. RNA interference
RNA interference vectors used in this study were obtained from
the National RNAi Core Facility in the Institute of Molecular Biology,
Academia Sinica (Taipei, Taiwan) as follows: pLKO.1-shRNA-p300-1#
(target sequence, 5′-CCTCACTTTATGGAAGAGTTA-3′); pLKO.1-shRNA-
p300-2# (target sequence, 5′-TACACTAGAGACACCTTGTAT-3′).
3. Results
3.1. Increased degradation reduces p300 levels during mitosis
and tumorigenesis
Many studies indicated that post-translational modiﬁcation of pro-
teins, such as the acetylation of histones, is critical for protein activity
[1,2]. Because p300 is an acetyl transferase, we investigated the regula-
tion of p300 during cell cycle progression and cancer formation. p300
decreased in mitotic cells, lung tumor tissue, and cancer cells withdazole-treatedmitotic HeLa cells were harvested to react with different dosages of alkaline
. Samples were analyzed by immunoblotting with antibodies against p300 and Sp1. B. The
g anti-p300 antibodies. IP sampleswere analyzed by immunoblot using antibodies against
main organization of p300 and a schematic diagram of GST-p300 truncation are shown:
and -3), CREB-binding domain (KIX), bromodomain (Br), histone acetyltransferas domain
(amino acids 2–331, 302–670, 565–966, 952–1145, 1964–2197 or 2188–2375) and GST-
vitro kinase assay. The truncated p300 proteins labeled with 32P-ATP were assessed using
roteins level as an internal control (lanes 8–14). The GST-nucleolin fragment (amino acids
1145 or 2188–2375) and its mutants (GST-p300-S1038A or -S2039A) were expressed in
CDK1, run the SDS-PAGE and autoradiography ﬁnally (lanes 1–4), and the levels of these
nd peptides with phosphorylation at Ser1038 or Ser2039 were synthesized to do dot blot
-p300 (S2039) antibodies (a). Peptide without phosphorylation and peptides with phos-
(S1038) antibodies (b). Normal or mitotic HeLa cells were harvested for immunoblotting
lin B1 and tubulin (c).
1140 S.-A. Wang et al. / Biochimica et Biophysica Acta 1843 (2014) 1135–1149high metastasis activity, but the mRNA level did not change during cell
cycle progression (Fig. 1A and B). To further investigate the behavior of
p300 during the cell cycle, we treated cellswith nocodazole for different
lengths of time (Fig. 1C(a)). p300 was gradually up-shifted and p300protein expression was abolished as the cells entered mitosis. Simulta-
neously, the acetylation of histone H3 gradually decreased. In contrast,
when cells were released from nocodazole treatment (Fig. 1C(b)), the
trend reversed as cells progressed from mitosis to interphase. Most
1141S.-A. Wang et al. / Biochimica et Biophysica Acta 1843 (2014) 1135–1149p300 was localized to the nucleus, where its concentration decreased
during prophase, metaphase, and anaphase and increased during the
interphase and telophase. The level of Sp1, used as an internal control,
did not change during the cell cycle [40] (Fig. 1D). HA-p300 levels de-
creased in HeLa cells treated with nocodazole (Fig. 1E). To exclude the
possibility that p300 downregulation was a side effect of nocodazole
treatment, cells were synchronized by double thymidine block at the
G1/S phase transition and then released for 10 h into mitosis (Fig. 1F).
Indeed, p300 levels were decreased during mitosis. To determine the
mechanism bywhich p300was downregulated duringmitosis, the pro-
tein half-life of p300 wasmeasured by treating normal andmitotic cells
with cycloheximide (Fig. 1G). The half-life of p300 was 6 h in normal
cells, but decreased to 1.5 h in mitotic cells, suggesting that a decrease
in protein stability reduced p300 levels during mitosis.
3.2. p300 phosphorylation on Ser1038/Ser2039 induces p300 degradation
during mitosis and tumorigenesis
Whether the reduction in p300 levels in mitotic and malignant cells
related to the band-shift of p300 observed in immunoblots required fur-
ther investigation. Initially, to determine whether phosphorylation
caused the band shift, we performed an in vitro phosphatase assay
with alkali phosphatase (CIP). Bands corresponding to p300 and
Sp1, used as a positive control, shifted downward in the presence of
CIP (Fig. 2A). A previous study showed that CDK1 phosphorylates
p300 during mitosis [41], but the phosphorylation residue(s) and the
function by CDK1were not established. Therefore, we performed an im-
munoprecipitation assay to study the interaction between p300 and
CDK1 (Fig. 2B). p300 interacted with CDK1 during mitosis. Next, we
constructed plasmids encoding truncated or mutated forms of p300
and expressed them in E. coli (Fig. 2C). First, 6 truncated fragments
(i.e., GST-p300 [2–331], GST-p300 [302–670], GST-p300 [565–966], GST-
p300 [952–1145], GST-p300 [1964–2197], and GST-p300 [2188–2375])
were used in CDK1 in vitro kinase assays, with GST-nucleolin (599-710)
as a positive control [42] (Fig. 2D, lane 7). Activated CDK1phosphorylat-
ed 2 of the truncated proteins, GST-p300 [952–1145] and GST-p300
[1964–2197] (Fig. 2D, lanes 4 and 5). Previous studies have demonstrat-
ed that the consensus CDK1phosphorylationmotif is (S/T)PX(K/R) [43].
When Ser1038 and Ser2039 were mutated in GST-p300 (952–1145)
and GST-p300 (1964–2197), respectively, the phosphorylation signal
was nearly abolished, suggesting that CDK1 phosphorylated p300 at
Ser1038 and Ser2039 (Fig. 2E).
To conﬁrm that endogenous p300 was phosphorylated at these 2
sites during mitosis and tumor formation, we developed 2 phospho-
speciﬁc antibodies, anti-phospho-p300 (Ser1038) and anti-phospho-
p300 (Ser2039) (Fig. 2F). The antibodies recognized phospho-peptides,
but not nonphospho-peptide, indicating that they were highly speciﬁc
(Fig. 2F(a)). Because a previous study showed that p300 is also phosphor-
ylated at Ser1037, the speciﬁcity of anti-phospho-p300 (Ser1038) anti-
bodies was also tested against a synthesized phospho-peptide modiﬁed
at Ser1037 (Fig. 2F(b)). The anti-phoapho-p300 (Ser1038) antibodies
only recognized the phospho-peptidemodiﬁed at Ser1038.When endog-
enous phosphorylation was examined, p300 was phosphorylated at
Ser1038 and Ser2039 in mitotic cells (Fig. 2F(c)). Taken together, these
results indicate that Ser1038 and Ser2039 are phosphorylated in cellsFig. 3. Involvement of p300 phosphorylation at Ser1038/2039 in its protein stability.A. Cell lysa
hibitor, (a), or knockdown of CDK1 by shRNA-CDK1 (b) were harvested for immunoblot with
and tubulin. B. HeLa cells with U0126, an ERK1/2 inhibitor, treatment were harvested for i
(S2039), phospho-ERK1/2, ERK1/2 and tubulin. C. HA-p300-WT, HA-p300-S1038A, HA-p300-S
was collected to performWestern analysis with anti-HA antibodies. Tubulin was a loading con
cells for 24 h, and then sampleswere collected for immunoblottedwithHAantibodies. E. HeLa ce
followed by treatment of cycloheximide for indicated time points and samples were harvested
three independent experiments, the level of HA-p300 protein was quantiﬁed and normalized
and **P b 0.01) (b). F. HA, HA-p300-WT or HA-p300-S2A expressing HeLa cells were harvested
with immunoblotting using anti-HA and anti-tubulin antibodies. G. Normal or mitotic HeLa cel
bodies against p300, cyclin B1 and tubulin. H. HA-p300-WT or HA-p300-S2A expressing HeLa ce
samples were then analyzed with immunoblotting using antibodies against HA, FBXO3, Sp1.stayed on mitosis; furthermore, phosphorylation might modulate p300
protein stability.
Next, a CDK1 inhibitor, roscovitine, and CDK1-shRNA were used to
block CDK1 activity and knockdown CDK1 expression, respectively,
and the effects on p300 level and phosphorylation were examined
(Fig. 3A). Loss of CDK1 decreased p300 phosphorylation, but increased
the p300 level. Because p300 regulates numerous genes during cancer
development, we investigated whether other kinases also phosphory-
lated at these two residues. The effects of various kinases inhibitors on
p300 phosphorylation at Ser1038 and Ser2039 were examined. Only
U0126, an ERK1/2 inhibitor, also inhibited p300 phosphorylation and
increased p300 levels. This result indicated that ERK1/2 might also reg-
ulate p300 protein stability, implying that p300 was phosphorylated at
Ser1038 and Ser2039 at interphase as well as at mitosis (Fig. 3B). To
study the relationship between p300 phosphorylation and stability,
plasmids encoding HA-p300-WT and the mutants, HA-p300-S1038A,
HA-p300-S2039A, and HA-p300-S2A, were constructed. Each plasmid
was transfected into HeLa cells, and the protein level in the mitotic
cells was assessed (Fig. 3C). Compared to the level of wild-type
HA-p300-WT, the levels of all the mutants, particularly HA-p300-S2A,
increased. In addition, a plasmid encoding the mutant, HA-p300-S2D,
was constructed to mimic the bi-phosphorylated form of p300 and
transfected into HeLa cells (Fig. 3D). In mitotic cells, the level of
HA-p300-S2D was lower than that of HA-p300-WT and HA-p300-S2A.
To further demonstrate the role of phosphorylation in determining
p300 stability, we also transfected plasmids encoding HA-p300-WT,
HA-p300-S2A, or HA-p300-S2D into HeLa cells and measured protein
half-life in the presence of cycloheximide without nocodazole
treatment (Fig. 3E, panels a and b). The half-life of HA-p300-WT (ap-
proximately 6 h)was shorter than that of HA-p300-S2A (approximately
9 h) and longer than that of HA-p300-S2D (approximately 3 h), suggest-
ing that phosphorylation at Ser1038 and Ser2039 is important for p300
protein stability. The ubiquitination of HA-p300-WT and HA-p300-S2A
was also compared (Fig. 3F). Ubiquitination of HA-p300-S2A was
lower, indicating that Ser1038 and Ser2039 phosphorylation regulated
p300 degradation in a proteasome-dependent manner. Treatment
with MG132, a proteasome inhibitor, attenuated the decrease in p300
observed in mitosis (Fig. 3G). Previous studies indicated that FBXO3, a
component of the SCF ubiquitin ligase complex that ubiquitinates pro-
teins intended for proteasomal degradation, plays a role in p300 degra-
dation [44]. In this study, the HA-p300-S2A decreased the interaction
of p300 with FBXO3, providing further evidence that phosphorylation
at Ser1038 and Ser2039 increases the p300 degradation through a
proteasome-dependent pathway (Fig. 3H). In conclusion, p300 phos-
phorylation at Ser1038 and Ser2039 is critical for p300 degradation
during mitosis and interphase.
3.3. p300 phosphorylation contributes to cell cycle progression by
promoting chromatin condensation
Previous studies indicate that histone H3 is acetylated by p300 [45];
herein we found that p300 decreased in mitotic cells. Therefore, we
were investigated whether phosphorylation of p300 affected the acety-
lation of histone H3.Mutation of S1038 and S2039 increased histone H3
acetylation in cells treated with or without nocodazole, indicating thattes of nocodazole treated HeLa cells in the absence or presence of roscovitine, a CDK1 in-
antibodies against p300, phospho-p300 (S1038), phospho-p300 (S2039), CDK1, cyclin B1
mmunoblotting with antibodies against p300, phospho-p300 (S1038), phospho-p300
2039A or HA-p300-S2A plasmids was transfected into HeLa cells for 24 h and then lysate
trol. D. HA-p300-WT, HA-p300-S2A or HA-p300-S2D plasmids was transfected into HeLa
lls transfectedwithHA-p300-WT,HA-p300-S2A andHA-p300-S2Dplasmids, respectively,
for Western blotting with anti-HA antibodies. Tubulin was as a loading control (a). After
with that of tubulin. Statistical analysis was performed using Student's t test (*P b 0.05,
for immunoprecipitation assay with anti-ubiquitin antibodies. IP samples were analyzed
ls treated with MG132, a proteasome inhibitor, were harvested for immunoblot with anti-
lls were harvested for immunoprecipitation assaywith anti-IgG and anti-HA antibodies. IP
Fig. 4. Effect of p300 phosphorylated at Ser1038/2039 on cell-cycle progression. A. HeLa cells transfected with HA-p300-WT, HA-p300-S2A individually were treated with nocodazole for
16 h, and then samples were collected to perform the immunoblotting assay using anti-acetyl-H3, anti-hstone H3 and anti-tubulin antibodies. HA-control, HA-p300-WT or HA-p300-S2A
plasmidwas transfected into HeLa cells and then treatedwith double-thymidine. Samples were collected at indicated time after removing the thymidine to perform theWestern blotting
using antibodies against p-H3 (S10), histone H3 and tubulin (B), and Flow cytometry assay (C). HA-control, HA-p300-WT or HA-p300-S2A plasmids were transfected into HeLa cells, and
then were treated with nocodazole for 16 h. After removing nocodazole, cells were harvested at indicated time forWestern blotting using antibodies against p-H3 (S10), histone H3 and
tubulin (D), and ﬂow cytometry assay (E).
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Fig. 5. Role of p300 phosphorylation at Ser1038/Ser2039 in chromosome condensation inmitotic cells. A. HA-p300-WT or HA-p300-S2A plasmid was transfected into HeLa cells for 24 h,
and then cells were treatedwith thymidine, then releasing for 10 h to partially synchronize the cells onmitosis. Immunoﬂuorescemce assaywas performedwith anti-p300 and anti-HP-1
antibodies combinedwith secondary antibodies conjugatedwith Cy5.DAPIwasused to stain the chromosome. B. After calculating 100metaphase cellswithHA-p300-WTorHA-p300-S2A
expression, the ratio of “A” form and “B” form was presented. C. GFP-p300-WT (a) and GFP-p300-S2A (b) expression HeLa cells synchronized at G2/M with nocodazole treatment, then
remove nocodazole to record the cell growth within 240 min by time-lapse. Arrows indicate the cells with GFP-p300 expression. Statistical analysis was performed using Student's t test
(*P b 0.05 and ***P b 0.001).
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1144 S.-A. Wang et al. / Biochimica et Biophysica Acta 1843 (2014) 1135–1149p300 phosphorylation at these 2 residues affected histone H3 acetyla-
tion in mitosis and interphase (Fig. 4A). Next, to determine whether
mutation of p300 affected cell cycle progression, we used a double-
thymidine block to synchronize cells in G1 phase and monitored entryinto mitosis (Fig. 4B and C), and we used nocodazole to release p300-
overexpressing cells from mitosis (Fig. 4D and E). The level of histone
H3 Ser10 phosphorylation, amitotic marker, was lower in cells express-
ing HA-p300-S2A than in cells expressing HA-p300-WT (Fig. 4B). Eight
1145S.-A. Wang et al. / Biochimica et Biophysica Acta 1843 (2014) 1135–1149hours after releasing the thymidine block, approximately 40% of
wild-type cells had entered mitosis, in contrast to 32% and 21% of cells
expressing HA-p300-WT and HA-p300-S2A, respectively, implying
that loss of p300 as a result of phosphorylation is necessary for the
cell entry into mitosis (Fig. 4C). Moreover, 90 min after release from
nocodazole treatment, phosphorylation of histone H3 at Ser10 was
nearly abolished in wild-type cells and in cells expressing HA-p300-
WT overexpression, but persisted in cells expressing HA-p300-S2A
(Fig. 4D). Two hours after release from nocodazole treatment, only
22% of wild-type remained in mitosis, in contrast to 26% and 41% cells
overexpressing HA-p300-WT and HA-p300-S2A, respectively, indicat-
ing that maintenance of the p300 level in mitotic cells prevents cells
from exiting mitosis (Fig. 4E).
Because the acetylation of histone H3 relates to chromatin conden-
sation, chromatin condensation in p300 overexpressing cells was stud-
ied (Fig. 5). The chromosomal volume in mitotic cells overexpressing
HA-p300-S2A was larger than in mitotic cells overexpressing HA-
p300-WT (Fig. 5A and B), suggesting that p300 is important for chromo-
somal packaging. Finally, after release from nocodazole treatment, HA-
p300-WT- and HA-p300-S2A-overexpressing cells were recorded by
time-lapse microscopy (Fig. 5C). Mitotic cells expressing HA-p300-S2A
remained round at all of the record timepoints, indicating thatmutation
of Ser1038 and Ser2039 disrupted cell cycle progression. Taken togeth-
er, our results show that p300 phosphorylation at Ser1038 and Ser2039
is important for cell cycle progression because it facilitates complete
chromosomal packaging, which promotes cancer cells proliferation.
3.4. Phosphorylation of p300 enhances the proliferation and metastasis
activity of lung adenocarcinoma cells
Many previous studies have investigated the role of p300 in the gen-
esis of various cancers [14,30]; they indicate that p300 has different ef-
fects in different types of cancers. Here, we studied the effect of p300
phosphorylation on lung cancer. To characterize the role of p300 and
phospho-p300 in proliferation and metastasis, we ﬁrst measured p300
phosphorylation levels in CL1-0 and CL1-5 cells, which exhibit low
and high metastasis activities, respectively [39,46](Fig. 6A). Compared
with CL1-0 cells, CL1-5 cells had higher phospho-p300 levels and great-
er invasive ability. Therefore we knocked down p300 in CL1-0 cells and
overexpressed p300 wild-type and mutant proteins in CL1-5 cells to
study the effects of p300 on cellular proliferation and morphology
(Fig. 6B panel a and Supplementary Fig. 1). There was no signiﬁcant al-
teration in the CBP- and p300-knockdown CL1-0 cells (Supplementary
Fig. 1). Cell number increased in p300-silenced CL1-0 cells, but de-
creased in the HA-p300- and HA-p300-S2A-expressing CL1-5 cells, sug-
gesting that p300 negatively regulates lung cancer cell growth (Fig. 6B,
panel b). Further study showed that overexpression of p300 increased
the caspase 3 cleavage, implying that higher level of p300 facilitates
lung cancer cell apoptosis (Supplementary Fig. 2). Furthermore, the
migratory area of HA-p300-S2A-expressing cellswas signiﬁcantly larger
than that of wild-type p300-transfected cells when assessed in wound-
healing assays (Fig. 6C). In addition, expression of HA-p300-S2A
inhibited the migration (Fig. 6D, panels a and b), and decreased the
invasiveness of CL1-5 cells (Fig. 6E, panels a and b), suggesting that
phosphorylation of p300 in CL1-5 cells enhances cell metastasis. Taken
together, our results indicate that p300 acts a tumor suppressor to
inhibit the proliferation and metastasis of lung cancer cells.Fig. 6. Effect of p300 phosphorylation at Ser1038/2039 on lung cancer. A. Lung cancer cell lines,
p300 (pS2039), anti-CDK1, and anti-tubulin antibodies. B. The p300was silenced by sh-p300#1
ing cells were counted after 24, 48, 72 and 96 h incubation (b). C. HA-control, HA-p300-WT or
healing assaywas performed and themigrated cell pictures were taken at 0, 12, 24, and 36 h (a
are representative of three independent experiments and the percentage was normalized w
transfected cells was determined using transwell chambers as described in Materials and meth
of three independent experiments and the percentage was normalized with control. Statistical
determined usingMatrigel-combined transwell chambers as described inMaterials andmethod
three independent experiments and the percentage was normalized with control (b). Statistic3.5. p300 phosphorylation regulates the metastasis-related genes expression
Our results showed that phosphorylation of p300 by CDK1 at
Ser1038 and Ser2039 repressed the proliferation andmetastasis activity
of lung cancer cells in vitro. In human lung tissue, we found that p300
was decreased and CDK1 was increased in the tumorous region of a
clinical lung cancer specimen, when compared to levels in the non-
tumorous lung area (Fig. 7A). Previous studies indicate that p300 regu-
lates MMP-9 [47]. Here we found that knockdown of p300 increased
MMP-9 expression, but did not alter MMP-7 expression (Fig. 7B). To
study the relationship between p300 and the expression of these
metastasis-related genes, endogenous p300 was knocked down and
metastasis-related proteins expression was measured (Fig. 7C). When
p300 was knocked down, the levels of vimentin, β-catenin, N-cadherin
and c-myc increased. Additionally, CL1-5 cells were transfected with
plasmids encoding HA-control, HA-p300-WT, HA-p300-S1038A, HA-
p300-S2039A, and HA-p300-S2A, and the expression of epithelial-
mesenchymal transition (EMT)moleculeswas assessed (Fig. 7D). The ex-
pression of vimentin and β-catenin decreased in cells overexpressing
p300, particularly in cells expressing the HA-p300-S2Amutant. Taken to-
gether, these data indicate that phosphorylation of p300 is important for
mediating the expression of EMT molecules and thereby for regulating
cell metastasis.
Finally, we assessed p300 levels and phosphorylation in vivo. In
immunohistochemistry (IHC) staining, p300 levels were lower in lung
tumor tissues from KrasG12D-induced lung cancer mice and from pa-
tientswith lung adenocarcinoma,when comparedwith levels in normal
tissue. Conversely, the levels of p-p300 (S1038), p-p300 (S2039),
β-catenin and c-myc in lung tumor tissues were higher [48,49]
(Fig. 7E and F). The results indicate that p300 is downregulated in
lung adenocarcinoma, whereas phospho-p300 (S1038), phospho-p300
(S2039), vimentin and c-myc, which are important for lung cancer
malignancy, are upregulated.
4. Discussion
In this study, we found that CDK1 in mitosis and ERK1/2 in
interphase phosphorylated p300 at Ser1038 and Ser2039 during tumor-
igenesis. Phosphorylation induced p300 degradation in mitosis, which
repressed histone H3 acetylation and thereby altered cell cycle progres-
sion. p300 also modulated oncogene expression in interphase, leading
to lung cancer progression (Fig. 8).
The transcriptional co-activator p300 is essential for physiologic and
pathologic processes including cell cycle regulation, differentiation,
tumorigenesis, and apoptosis [9]. Dysregulation of p300, including mu-
tation and alteration of protein levels, has been implicated in many dis-
eases, including cancer [24]. Therefore, p300 must be tightly regulated
to maintain normal cellular processes. Many post-translational modiﬁ-
cations, including phosphorylation and acetylation, have been implicat-
ed in the regulation of p300 turnover [50]. Previous studies showed that
acetylation is a critical self-amplifying mechanism that promotes the
rapid accumulation of p300 within cells under physiologic stress [51].
In addition to acetylation, site-speciﬁc p300 phosphorylation mediates
distinct structural and functional alterations and regulates p300 stabili-
ty [50]. For example, Akt regulates p300 transcriptional activity by
increasing its stability and maintains p300 levels in different cell sys-
tems. Thus, Akt is also a critical regulator of p300 turnover [30,34]. InCL1-0 and CL1-5, were harvested for immunoblotting assay with anti-p300 (pS1038), anti-
and sh-p300#2 to count the cell number (a). HA, HA-p300-WT andHA-p300-S2A express-
HA-p300-S2A plasmids were transfected into HeLa cells for 24 h individually, and wound-
). The relative distance between themargins of cells was calculated for quantiﬁcation. Data
ith control (b). D. The migration ability of HA-control, HA-p300-WT- or HA-p300-S2A-
ods (a). The relative cell number was calculated for quantiﬁcation. Data are representative
analysis was performed (b). E. Effect of p300 and mutated p300 on invasive ability of cells
s (a). The relative cell number was calculated for quantiﬁcation. Data are representative of
al analysis was performed using Student's t test (*P b 0.05, **P b 0.01, and ***P b 0.001).
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Fig. 8. Schematic diagram illustrates themolecularmechanism of p300 phosphorylation at
Ser1038/2039 involved in lung cancer formation.
1147S.-A. Wang et al. / Biochimica et Biophysica Acta 1843 (2014) 1135–1149contrast, the interaction of p300 with p38 MAPK results in p300
degradation [35,36]. p300 phosphorylation and degradation are also
functionally linked to DNA damage responses. Besides, DNA damage-
induced p300 degradation is coupled to p300 phosphorylation at
Ser1834, which is mediated by p38 MAPK and Akt [36]. In the present
study, we demonstrated that CDK1-induced p300 phosphorylation at
Ser1038/Ser2039 leads to p300 degradation, which promotes mitosis
progression. Although a previous study showed that CDK1 phosphory-
lated p300 in vitro [41], the phosphorylation site(s) were not identiﬁed
and the effects of p300 phosphorylation were not explained. Here, we
used in vitro kinase assays to identify the sites phosphorylated by
CDK1, and we established that phosphorylation induces p300 degrada-
tion. However, as shown in Fig. 1, although p300 levels decreased as
cells entered prophase, levels quickly increased during telophase. The
mechanism by which p300 induces chromosomal condensation during
mitosis remains unclear and required further study. Additionally,
we found that p300 was not phosphorylated by CDK1 during mitosis
in all cells. For instance, during mitosis, p300 phosphorylation at
Ser1038/Ser2039 increased and p300 stability decreased in HeLa and
A549 cells, but not in H1299 cells (data not shown). Furthermore, the
unphosphorylated HA-p300-S2A mutant was more stable than wild-Fig. 7. Effect of p300 phosphorylation at Ser1038/2039 on oncogenes expression. A. The level o
CDK1 antibodies. B. Samples harvested from CL1-0 cells with knockdown of p300 by shRNA-p
against p300, MMP9, MMP7 and Tubulin. ThemRNA levels of p300 and GAPDHwere studied us
CL1-0 cells for 48 h and cells were subsequently harvested for performing immunoblotting wit
using primers for p300 and GAPDH, respectively. D. HA-control, HA-p300-WT, HA-p300-S1038A
then cells were harvested for performing Western blotting using antibodies against HA, vimen
were determined in normal and tumor tissues from bitransgenic mice (E), and in human norm
with antibodies against p300, p-p300 (p-S1038), p-p300 (p-S2039), anti-β-catenin and anti-c-type p300 in HeLa and A549 cells, but not in H1299 cells (data not
shown), implying that the p300 phosphorylation by CDK1 is cell-type
speciﬁc. Might be with different molecular mechanisms existed in the
different cell lines to regulate p300 phosphorylation at Ser1038 and
Ser2039. For instance, other factor(s) expressed in HeLa and A549
cells but not in H1299 cellsmight be essential for p300 phosphorylation.
However, the mechanism remains unknown and required further
study. In addition, HA-p300-S2A expression also induced the S-phase
arrest, implying that p300 phosphorylation at Ser1038/Ser2039
affects more than protein stability. Whether p300 phosphorylation at
Ser1038/Ser2039 also affects p300 transcriptional activity merits
further study.
Cyclin B is a central regulator of the transition from G2 phase to mi-
tosis [52]. Recent studies have shown that p300 binds to the cyclin B1
promoter and cooperates with the transcription factor NF-Y to activate
the transcription of cyclin B1 [53]. Cyclin B1 is downregulated when
cells exit mitosis. Here, we found that p300 was phosphorylated by
CDK1 during mitosis and then degraded, which would putatively halt
the transcriptional activation of cyclin B1. Thus, in the absence of p300
degradation, high p300 levels duringmitosis would result in mitotic ar-
rest. To evaluate this hypothesis, we utilized an unphosphorylated p300
(HA-p300-S2A) to analyze the effect of p300 phosphorylation onmitot-
ic progression by ﬂow cytometry. The results conﬁrmed that the
absence of p300 phosphorylation led to mitotic arrest (Fig. 4C and E).
Furthermore, by analyzing the level of phosphorylated histone H3, a
knownmitotic marker, we showed that the absence of p300 phosphor-
ylationdelayedmitotic exit (Fig. 4B andD). Additionally, bymaintaining
high levels of acetylated histone H3, unphosphorylated p300 also inter-
fered with chromatin condensation during mitosis (Fig. 6). However,
because not all p300-S2A-overexpressing cells arrested during mitosis,
we suggest that other molecules, in addition to p300, are responsible
for maintaining smooth cell cycle progression.
Having shown that p300 is phosphorylated by CDK1 duringmitosis,
we next examined the role of the p300 phosphorylation in mitosis pro-
gression. However, many previous studies have shown that CDK1 is also
expressed in many types of cancer [54–56]. In this study, several ﬁnd-
ings indicated the phosphorylation of p300 at Ser1038 and Ser2039
occurred in interphase and mitosis. First, CDK1 and ERK1/2 both phos-
phorylated p300, which implied that p300 is also phosphorylated
at interphase. During tumorigenesis, ERK1/2 phosphorylated p300
and thereby decreased its protein stability. However, phosphorylation
of p300 at Ser1038 and Ser2039 might have other effects such as
altering p300 transactivating activity, but this requires further study.
Second, when HA-p300-S2A was overexpressed in cancer cells, several
metastasis-related genes, including β-catenine and vimentin were
downregulated, suggesting that HA-p300-S2A alters their gene regula-
tion, which is common in interphase. Finally, in samples from clinical
lung cancer patient and KrasG12D-induced lung cancer mice, the phos-
phorylation of p300 at Ser1038 and Ser2039was higher in tumorous re-
gions than in non-tumorous areas. The in vitro and in vivo data reported
here support the conclusion that p300 phosphorylation at Ser1038 and
Ser2039 occurs not only in mitosis, but also in interphase and tumori-
genesis. p300phosphorylation inmitosis and interphasemight enhance
cell proliferation and metastasis respectively, which would promote
cancer progression.
Previous studies demonstrated that the p300/CBP complex primarily
functions as a transcription cofactor through its interaction with af p300 and CDK1 was studied by immunohistochemistry assay using anti-p300 and anti-
300#1 and shRNA-p300#2 were used to do the immunoblotting assay using antibodies
ing RT-PCR. C. Different p300 shRNAs (#1 or #2) or scrambled shRNAwas transfected into
h antibodies against p300, vimentin, β-catenin, N-cadherin, c-Myc and tubulin or RT-PCR
, HA-p300-S2039A or HA-p300-S2A plasmidwas transfected into CL1-5 cells for 24 h, and
tin, β-catenin and tubulin. The levels of p300, p300 phosphorylation, β-catenin and c-myc
al and lung adenocarcinoma tumor tissues (F) by using an immunohistochemistry assay
myc antibodies.
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Fos), transforming viral proteins (e.g., E1A, E6, and large T antigen),
and tumor-suppressor proteins (e.g., p53, E2F, Rb, Smads, RUNX, and
BRCA1) [10,57–68]. Previous studies have also shown that p300
truncation mutants occur in solid tumors and are associated with the
loss of the second p300 allele [15,24]. Moreover, chromosomal rear-
rangements produce translocation involving the p300 and CBP genes
in leukemia and lymphoma [15]. Recently, it was reported that breast
and colorectal carcinomas expressed p300 at extremely low levels
[15]. Moreover, both p300 and CBP function as tumor suppressors in
mice, where their deﬁciency results in the development of hematologi-
calmalignancies. The role of p300 in pathways critical for tumorigenesis
(e.g., p53, Rb-E2F, or TGF-β pathways) could be a mechanism by which
p300 contributes to cancer formation [15]. In the present study, we
overexpressed wild-type and mutant p300 in CL1-5 cells. p300 overex-
pression attenuated cellular invasiveness and downregulated the ex-
pression of many EMT molecules (Fig. 7). Although overexpression of
p300 in CL1-5 cells induced EMT, this does not alter CL1-0 cellular mor-
phology under knockdown of p300, implying that regulation of other
factor(s) is essential for morphologic alteration from CL1-0 to CL1-5
cells (Supplementary Fig. 1).
Although previous studies showed that p300 co-activators repressed
c-myc [69], themechanismwas unclear. In invasive tumor cells, we pro-
pose that phosphorylation and downregulation of p300 reduce the
expression of tumor suppressor genes and induce the expression of
the EMT molecules. Consistently, HA-p300-S2A overexpression, more
so than HA-p300-WT overexpression, induced p53 and FOXO3a, imply-
ing that p300 suppresses lung tumorigenesis speciﬁcally bymodulating
themetastasis activity (data not shown). In this study, p300 knockdown
increased the levels of vimentin, β-catenin, N-cadherin and c-myc
(Fig. 7). Previous reports showed that p300 negatively regulates the
expression of c-myc [46], which in turn regulates tumor metastasis
speciﬁcally through its effects on cancer cell invasion and migration.
β-catenin promotes tumor malignancy by translocating to the Recent
studies have shown that vimentin is closely linked with tumorigenesis
and metastasis [49]. Based on our results, we can reasonably propose
that p300 is a tumor-suppressor in lung cancer that inhibits cell prolif-
eration and metastasis. In addition, previous studies indicate that
c-Myc could be acetylated by CBP/P300 [70]. Here we found that p300
downregulation in lung cancer in vitro and in vivo enhanced c-Myc ex-
pression. The affected molecular mechanism of p300-mediated c-Myc
expression is required to be addressed in the future, and subsequently
turning on gene transcription related to metastasis in colon cancer
[45]. N-cadherin, commonly found in cancer cells, plays a pivotal role
in trans-endothelial migration [48]. Although the data shown in
Fig. 2F showed that S1038 and S2039 were principally phosphorylated
in mitosis, their phosphorylation levels also increased in the lung
tumor tissues from K-rasG12D-induced lung cancer mice and clinical
lung cancer patients. This suggests that other kinase(s) activated during
tumorigenesis phosphorylate p300 during interphase. The data shown
in Fig. 3A(a) demonstrated that ERK1/2 induces p300 phosphorylation
at these 2 sites. Our studies might help to explain why phosphorylation
of p300 at Ser1038 and Ser2039 also affects S-phase progression. In ad-
dition, because different ERK1/2 activities exist in the different cell lines
such as CL1-0 and CL1-5 cells, whichmight be the reason why there are
different phosphorylations of p300 found in the different cell lines.
However, how these 2 phospho-residues affect the S-phase is still un-
known and required further study.
In conclusion, phosphorylation reduces the stability of p300,
which contributes to cell cycle progression and tumor metastasis.
Many compounds that inhibit p300 activity have been developed for
cancer treatment. Therefore, the clariﬁcation of the role of p300 in
various tumor types might help future cancer therapies exploiting
p300 inhibitors.
Supplementary data to this article can be found online at http://dx.
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